Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 37 Carcinoma, Non-Small-Cell Lung 24 Squamous Cell Carcinoma of Head and Neck 18 Melanoma 17 Colorectal Neoplasms 16 Urinary Bladder Neoplasms 11 Breast Neoplasms 11 Liver Neoplasms 10 Biliary Tract Neoplasms 10 Small Cell Lung Carcinoma 9 Prostatic Neoplasms 9 Lung Neoplasms 9 Diabetes Mellitus, Insulin-Dependent, 12 9 Carcinoma, Renal Cell 9 Neoplasms 8 Cholangiocarcinoma 7 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Adenocarcinoma Of Esophagus 6 Stomach Neoplasms 5 Neoplasm Metastasis 5 Mesothelioma, Malignant 5 Fallopian Tube Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 3 Recurrence 3 Mesothelioma 3 Esophageal Squamous Cell Carcinoma 3 Endometrial Neoplasms 3

Interventions

tislelizumab 2 Oxaliplatin 2 tremelimumab 1 olaparib 1 durvalumab 1 apatinib 1 Tegafur 1 Immunotherapy, Adoptive 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Immunotherapy × tremelimumab × Clear all

NCT04169841 2024-02-13

GUIDE2REPAIR

Centre Georges Francois Leclerc

Phase 2 Active not recruiting

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡